Clinical Trial Update: Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

Open-label extension study of tocilizumab in generalized myasthenia gravis (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis Generalized

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Myasthenia Gravis, Generalized | Phase 2, Phase 3 | Status: UNKNOWN